Patents Examined by Gregg Polansky
  • Use of FK506 for the treatment of pulmonary arterial hypertension
    Patent number: 9474745
    Abstract: A method of reducing pulmonary arterial hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: October 25, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Edda Spiekerkoetter, Marlene Rabinovitch, Philip A. Beachy, David Solow-Cordero
  • Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
    Patent number: 9474732
    Abstract: The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% of 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: October 25, 2016
    Assignee: Mallinckrodt LLC
    Inventors: Thomas R. Prentice, Angela A. Strantz
  • Fungicidal composition comprising mancozeb and chlorothalonil
    Patent number: 9451769
    Abstract: Disclosed herein is a fungicidal composition comprising combination of fungicidally effective amount of mancozeb and a fungicidally effective amount of chlorothalonil in a predetermined ratio.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: September 27, 2016
    Assignee: UPL Limited
    Inventors: Jaidev Rajnikant Shroff, Vikram Rajnikant Shroff, Philip Wayne Robinson, Beth Errickson Sears, Prakash Mahadev Jadhav
  • Methods for treating leukemia and disorders mediated by CBF? and RUNX1 proteins
    Patent number: 9446048
    Abstract: A method for treating core binding factor (CBF) leukemia in a subject, comprising administering to a subject having CBF leukemia a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, that inhibits CBF? and RUNX1 binding in the subject, thereby treating the CBF leukemia.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: September 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Pu Liu, Wei Zheng, Juan Marugan, Noel T. Southall, Lea Cunningham
  • Non-hormonal steroid modulators of NF-?B for treatment of disease
    Patent number: 9434758
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: September 6, 2016
    Assignee: ReveraGen Biopharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Thiazolamine derivative and use thereof as anti-picornaviral infection medicament
    Patent number: 9428496
    Abstract: Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application thereof in the prevention and/or treatment of viral diseases induced by picornavirus. Also disclosed is a pharmaceutical composition containing the compound.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: August 30, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
  • Use of pemirolast
    Patent number: 9415051
    Abstract: According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: August 16, 2016
    Assignee: RSPR Pharma AB
    Inventors: Johan Raud, Carl-Johan Dalsgaard, Göran Tornling
  • Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics
    Patent number: 9403769
    Abstract: Small molecule inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) having the following formula: Formula (1) are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting PFK.FB3 enzymatic activity, methods of inhibiting glycolytic flux, and methods of treating tumors by administering an effective amount of a Formula I compound.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: August 2, 2016
    Assignees: Advanced Cancer Therapeutics, LLC, University of Louisville Research Foundation, Inc.
    Inventors: Pooran Chand, Jason A. Chesney, Brian F. Clem, Gilles H. Tapolsky, Sucheta Telang, John O. Trent
  • Compounds that treat malaria and prevent malaria transmission
    Patent number: 9375424
    Abstract: The invention provides methods and compounds for the treatment and prevention of malaria infection and transmission in a mammal by administering compounds of the invention to a mammal having or suspected of having a malaria infection. The invention also provides pharmaceutical compositions that can kill or arrest the growth of Plasmodium organisms, and especially Plasmodium falciparum, thereby preventing or blocking transmission of malaria as well as treating malaria infection.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: June 28, 2016
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Xin-zhuan Su, Jing Yuan, Dipak Raj, Sittiporn Pattaradilokrat, Ron Johnson, Ruili Huang
  • Methods of treating alzheimer's disease and pharmaceutical compositions thereof
    Patent number: 9375418
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 28, 2016
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Methods of treating a Bruton's Tyrosine Kinase disease or disorder
    Patent number: 9364476
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: June 14, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Steven Richard Witowski, William Frederick Westlin, III, Heather Lounsbury, Kathryn Stiede, Bruce A. Silver, Jay M. Mei
  • Diaminooxidase-containing pharmaceutical compositions
    Patent number: 9364437
    Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 14, 2016
    Assignee: SCIOTEC DIAGNOSTIC TECHNOLOGIES GMBH
    Inventors: Albert Missbichler, Franz Gabor, Herwig Reichl
  • Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
    Patent number: 9359355
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: June 7, 2016
    Assignee: AMGEN INC.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, Jr., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
    Patent number: 9359289
    Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising; the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: June 7, 2016
    Assignee: Intrexon Corporation
    Inventors: Robert Eugene Hormann, David W. Potter, Orestes Chortyk, Colin M. Tice, Glenn Richard Carlson, Andrew Meyer, Thomas R. Opie
  • Histone deacetylase inhibitors as therapeutic agents for Niemann-Pick type C disease
    Patent number: 9333222
    Abstract: Embodiments herein relate to the field of lysosomal storage disorders, and, more specifically, to methods of treating lysosomal storage disorders such as Niemann-Pick type C disease, for instance with inhibitors of histone deacetylases, particularly inhibitors of class 1 histone deacetylases. In various embodiments, methods of treating Niemann-Pick type C disease with inhibitors of class 1 histone deacetylases are described.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: May 10, 2016
    Assignees: University of Notre Dame du Lac, Cornell University
    Inventors: Olaf Wiest, Frederick R. Maxfield, Paul Helquist
  • Dexmedetomidine premix formulation
    Patent number: 9320712
    Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: April 26, 2016
    Assignee: HOSPIRA, INC.
    Inventors: Priyanka Roychowdhury, Robert A. Cedergren
  • Cyclohexylamine derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activities
    Patent number: 9315463
    Abstract: The present disclosure relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: April 19, 2016
    Assignee: Almirall, S.A.
    Inventors: Maria Prat Quinones, Silvia Fonquerna Pou, Carlos Puig Duran, Wenceslao Lumeras Amador, Jose Aiguade Bosch, Juan Francisco Caturla Jovaloyes
  • Compounds for the treatment of hepatitis C
    Patent number: 9303020
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: April 5, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, John F. Kadow
  • Methods and compositions for improving cognitive function
    Patent number: 9283203
    Abstract: This invention relates to compositions, and methods of use thereof, for (i) enhancing executive cognitive function(s) (for example, decision making, planning, working memory, multitasking, judgment, numerical problem-solving, reading comprehension), and/or (ii) increasing blood flow in brain vasculature, comprising administering to a subject in need thereof, certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: March 15, 2016
    Assignee: MARS, INCORPORATED
    Inventors: Stephen French, Amar P. Inamdar, Ian Andrew Macdonald, Susan T. Francis
  • Methods of providing weight loss therapy in patients with major depression
    Patent number: 9248123
    Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: February 2, 2016
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Eduardo Dunayevich, Gary Tollefson, David Dewitt